Epizyme, Inc. to Present at Piper Jaffray Conference on December 1,
2015

November 24, 2015 08:00 AM Eastern Standard Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company
creating novel epigenetic therapeutics for cancer patients, will
participate in the Piper Jaffray 27th Annual Healthcare
Conference at the Lotte Palace Hotel in New York on Tuesday, December 1
at 1pm ET.

A live webcast and archived replay for the conference will be available
by visiting the Investor Center of the Epizyme website at www.epizyme.com.

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company creating
novel epigenetic therapeutics for cancer patients. Epizyme has built a
proprietary product platform that the Company uses to create small
molecule inhibitors of chromatin modifying proteins (CMPs), such as
histone methyltransferases or HMTs. CMPs are part of the system of gene
regulation, referred to as epigenetics, that controls gene expression.
Genetic alterations can result in changes to the activity of CMPs,
making them oncogenic (cancer-causing). By focusing on the genetic
drivers of cancers, Epizyme's targeted science seeks to match the right
medicines with the right patients.

For more information, visit www.epizyme.com
and connect with us on Twitter at @EpizymeRx.